Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $6.67.
A number of research analysts have recently commented on IPHA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Innate Pharma in a research report on Tuesday, September 22nd. Citigroup raised shares of Innate Pharma from a “buy” rating to an “outperform” rating in a report on Tuesday, August 11th. UBS Group reaffirmed a “buy” rating on shares of Innate Pharma in a research note on Tuesday, August 11th. Leerink Partners raised shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price target on the stock in a research note on Tuesday, August 11th. Finally, HC Wainwright reiterated a “buy” rating on shares of Innate Pharma in a report on Monday, September 21st.
Check Out Our Latest Report on Innate Pharma
Innate Pharma Stock Performance
NASDAQ IPHA opened at $1.03 on Thursday. Innate Pharma has a fifty-two week low of $1.00 and a fifty-two week high of $2.71. The business has a 50 day moving average price of $1.57 and a two-hundred day moving average price of $1.69.
Innate Pharma Company Profile
Innate Pharma is a clinical-stage biotechnology company based in Marseille, France. It develops immunotherapies for cancer, with research focused on harnessing the body’s innate immune system to recognize and attack tumor cells. The company’s work includes antibody-based treatments and cell therapies, with investigational candidates being studied for blood cancers and other malignancies. Its pipeline includes lacutamab, an antibody candidate targeting KIR3DL2, and programs developed with pharmaceutical partners.
See Also
- Five stocks we like better than Innate Pharma
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
